UCL logo

UCL Discovery

UCL home » Library Services » Electronic resources » UCL Discovery

The immunohistochemical assessment of hypoxia, vascularity and proliferation in bladder carcinoma

Hoskin, PJ; Sibtain, A; Daley, FM; Saunders, MI; Wilson, GD; (2004) The immunohistochemical assessment of hypoxia, vascularity and proliferation in bladder carcinoma. Radiotherapy and Oncology , 72 (2) pp. 159-168.

Full text not available from this repository.

Abstract

Background and purpose: Hypoxia and proliferation are important determinants of radiation responsiveness; prospective measures of these before radiotherapy may enable individualisation of treatment schedules. Immunohistochemical techniques offer a potential means of achieving this in routine biopsy material. Material and methods: Cellular hypoxia as measured by pimonidazole fixation and immunohistochemistry has been evaluated in a series of human bladder cancers with dual staining of sections for pimonidazole and either the vascular markers, CD31/34, or proliferation markers, Ki-67 or cyclin A. Twenty one tumour specimens were examined suitable for the double staining technique. Results: The median hypoxic fraction was 9% (range 0-38). Seven tumours did not stain for pimonidazole and 11 exhibited necrosis. The mean vascular density ranged from 16.7 to 160.6 vessels per mm(2). The median hot spot count was 30 (range 16-43). There was a statistically significant increase in vessel density in hypoxic compared to oxic regions measured by both vessel density (P = 0.02) and hot spot count (P = 0.004). Proliferation indices decreased from oxic to hypoxic areas close to blood vessels. Conclusions: We have demonstrated that bladder cancer exhibits a range of hypoxia, proliferation and vascular density which may be used to form the basis for patient selection for hypoxia modification, accelerated radiotherapy and vascular targeting agents. (C) 2004 Elsevier Ireland Ltd. All rights reserved

Type: Article
Title: The immunohistochemical assessment of hypoxia, vascularity and proliferation in bladder carcinoma
Additional information: WoS ID: 000223463300005 JournalEnglishArticle41ELSEVIER SCI IRELAND LTDAIRLEY RE, 2003, INT J CANCER, V104, P85; AMELLEM O, 1991, CELL PROLIFERAT, V24, P127; ARTEEL GE, 1998, EUR J BIOCHEM, V253, P743; BEASLEY NJP, 2001, CANCER RES, V61, P5262; BEDFORD JS, 1974, BRIT J RADIOL, V47, P687; BEGG AC, 2001, ACTA ONCOL, V40, P924; BUSSINK J, 1998, BRIT J CANCER, V77, P57; CHAUDHARY R, 1999, ANTICANCER RES, V19, P3479; EVANS SM, 2001, AM J CLIN ONCOL-CANC, V24, P467; GIATROMANOLAKI A, 2001, CANCER RES, V61, P7992; HOCKEL M, 2001, J NATL CANCER I, V93, P266; HOSKIN PJ, 2003, BRIT J CANCER, V89, P1290; KAANDERS JHAM, 2002, CANCER RES, V62, P7066; KENNEDY AS, 1997, INT J RADIAT ONCOL, V37, P897; KOCH CJ, 1973, INT J RADIAT BIOL, V23, P67; KOUKOURAKIS MI, 2001, CLIN CANCER RES, V7, P3399; LARA PC, 1998, RADIOTHER ONCOL, V49, P163; NORDSMARK M, 2001, INT J RADIAT ONCOL, V49, P581; NORDSMARK M, 1996, INT J RADIAT ONCOL, V35, P701; OLIVE PL, 2000, BRIT J CANCER, V83, P1525; OOSTERHUIS JWA, 2000, CANCER, V88, P2598; OVERGAARD J, 1996, SEMIN RADIAT ONCOL, V6, P10; PETROVICH Z, 2001, AM J CLIN ONCOL-CANC, V24, P1; PETTERSEN EO, 1981, BRIT J CANCER, V43, P355; RALEIGH JA, 1995, ACTA ONCOL, V34, P345; RALEIGH JA, 1998, CANCER RES, V58, P3765; RALEIGH JA, 2000, CLIN CANCER RES, V6, P855; RAYLEIGH JA, 1999, RADIAT RES, V151, P980; SAGOL O, 2001, UROLOGY, V57, P895; SHWEIKI D, 1992, NATURE, V359, P843; SPIRO IJ, 1984, INT J RADIAT ONCOL, V10, P1275; TAKANO S, 1996, CANCER RES, V56, P2185; TOI M, 1995, BREAST CANCER RES TR, V36, P193; TOI M, 1995, CLIN CANCER RES, V1, P961; TOI M, 1994, JPN J CANCER RES, V85, P1045; TOMLINSON RH, 1955, BRIT J CANCER, V9, P539; TSANG RW, 2000, INT J RADIAT ONCOL, V46, P95; WEBSTER L, 1998, BRIT J CANCER, V77, P227; WEIDNER N, 1991, NEW ENGL J MED, V324, P1; WIJFFELS KI, 2000, BRIT J CANCER, V83, P674; WYKOFF CC, 2000, CANCER RES, V60, P70750AUG848JJCLAREHoskin PJ Mt Vernon Canc Ctr, CR UK Tumour Biol & Radiat Therapy Grp, Rickmansworth Rd, Northwood HA6 2RN, Middx, EnglandRADIOTHER ONCOLCUSTOMER RELATIONS MANAGER, BAY 15, SHANNON INDUSTRIAL ESTATE CO, CLARE, IRELAND
Keywords: AGENT, AGENTS, bladder cancer, bladder carcinoma, BREAST, breast cancer, BREAST-CANCER, CANCER, CARCINOMA, CERVIX, ENDOTHELIAL GROWTH-FACTOR, EXTREME HYPOXIA, FACTOR EXPRESSION, HYPOXIA, INTRINSIC MARKERS, Ki67, marker, MARKERS, NECK-CANCER, pimonidazole, PIMONIDAZOLE BINDING, proliferation, RADIATION, radiotherapy, THERAPY, TRANSITIONAL-CELL CARCINOMA, TUMOR ANGIOGENESIS, vascularity
UCL classification: UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences > Cancer Institute
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences > Cancer Institute > Research Department of Oncology
URI: http://discovery.ucl.ac.uk/id/eprint/36534
Downloads since deposit
0Downloads
Download activity - last month
Download activity - last 12 months
Downloads by country - last 12 months

Archive Staff Only

View Item View Item